Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated...
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Target Price
The average target price of PEPG is 9.5 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell